New drug duo aims to tackle tough lymphoma

NCT ID NCT03323151

Completed Disease control Sponsor: PrECOG, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured how many patients achieved a complete remission within the first year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ixazomib (Ninlaro) and ibrutinib (Imbruvica)
What this could lead to: If this combination works well, it could offer a new treatment option for people with mantle cell lymphoma that has come back or stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 43 participants, so results may not apply to everyone. Side effects from the drug combination could be serious, and the added benefit of ixazomib over ibrutinib alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Carle Cancer Center

Urbana, Illinois, 61801, United States
Georgia Cancer Center at Augusta University

Augusta, Georgia, 30912, United States
Gundersen Health System

La Crosse, Wisconsin, 54601, United States
Laura and Isaac Perlmutter Cancer Center at NYU

New York, New York, 10016, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
ProHealth Care

Waukesha, Wisconsin, 53188, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
University of Kansas

Overland Park, Kansas, 66210, United States
University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
University of Virginia

Charlottesville, Virginia, 22908, United States
University of Wisconsin

Madison, Wisconsin, 53792, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
West Virginia University

Morgantown, West Virginia, 26506, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.